Anti-VEGF treatment patterns and associated health care costs in Switzerland: findings using real-world claims data

相似書籍

• Comparison of Eylea® with Lucentis® as first-line therapy in patients with treatment-naïve neovascular age-related macular degeneration in real-life clinical practice: retrospective case-series analysis
  由: Böhni, Sophie C., et al.
  出版: (2015)
• Epidemiology and costs of multiple sclerosis in Switzerland: an analysis of health-care claims data, 2011–2015
  由: Blozik, Eva, et al.
  出版: (2017)
• Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland
  由: Reich, Oliver, et al.
  出版: (2017)
• Epidemiology and costs of diabetes mellitus in Switzerland: an analysis of health care claims data, 2006 and 2011
  由: Huber, Carola A, et al.
  出版: (2014)
• Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life
  由: Schmid, Martin K., et al.
  出版: (2015)